Top ▲

Lymphoma, non-hodgkin, familial

GtoPdb Disease Summaries

This section gives an overview of the disease, and where available shows the following:

  • Synonyms: Shows known synonyms for the disease.
  • Description: Gives a basic description/definition of the disease.
  • Database Link: External links to the same disease at the Disease Ontology, OMIM or Orphanet sites.
  • Immunopharmacology comments: General comments about the target's role in immunopharmacology, provided by GtoImmuPdb curators.
  • Associated with: Counts are displayed for the total targets the disease is associated with in GtoPdb. The counts of targets and ligands of immunological relevance associated to the disease are also shown.

More information can be found in the help pages.

✖
Disease ID:578
Name:Lymphoma, non-hodgkin, familial
Associated with:4 targets
2 immuno-relevant ligands
Synonyms
Non-Hodgkin lymphoma
Description
A lymphoma that is characterized as any kind of lymphoma except Hodgkin's lymphoma. Symptoms include enlarged lymph nodes, fever, night sweats, weight loss, and lethargy.
Database Links
Disease Ontology: DOID:0060060
OMIM: 605027

Targets

GtoPdb Disease Summaries - Targets

Click on the target name to link to its detailed view page

Where available, information is display on the role of the target in the disease; drugs which target the disease and their therapeutic use and side-effects.

If there is mutation data curated in GtoPdb this is indicated, with a link back to the appropriate section on the target detailed view page

Immuno ligand interactions - If available, a table of immuno-relevant ligands is shown. These ligands have been curated as having an association to the disease and possess interaction data with the target in GtoPdb. The approval status of the ligand is shown, along with curator comments and an indication of whether the target is considered the primary target of the ligand.

More information can be found in the help pages.

✖
Key to terms and symbols
Caspase 10
TLR9
B-Raf proto-oncogene, serine/threonine kinase
References:  3
regulator of G-protein signaling 5
Comments:  RGS5 transcripts are greatly increased in eight subtypes of lymphoma.
References:  4

Ligands

GtoPdb Disease Summaries - Ligands

Click ligand name to view ligand summary page

  • Approved: If the ligand is an approved drug this is indicated, along with approval bodies.
  • Immuno: Immuno icon indicates the ligand is immuno-relevant

Click the arrow in the final column to expand comments

  • Immuno Disease Comments: Curatorial comments specifically added as part of GtoImmuPdb. They give more information on the association between the ligand and disease in the context of immunopharmacology.
  • Clinical Use: General clinical comments relating to the ligand and may not necessarily be specific to the disease in question. With hyperlink to more details on the ligand summary pages.
  • Bioactivty Comments: Curatorial comments specifically about the compounds biological activity - with hyperlink to more details on the ligand summary pages.

More information can be found in the help pages.

✖
Key to terms and symbols Click ligand name to view ligand summary Click column headers to sort
Ligand References Clinical and Disease comments
IL-21 2
Immuno Disease Comments: HL cancer cells produce IL-21 which could explain the clustering of other immune cells around HL cells observed in vitro.
Bioactivity Comments: IL-21 has been shown to eliminate glioblastoma multiforme cells via activation of the cytolytic reactivity of Vγ9Vδ2 T cells in vitro and in an in vivo model [1]. These findings suggest that IL-21-sensitized allogeneic human Vγ9Vδ2 T cells might offer a novel immunotherapeutic approach for the treatment of glioblastoma multiforme. | View biological activity
lymphotoxin-α
Immuno Disease Comments: Approved therapy for this indication.

References

Show »

1. Joalland N, Chauvin C, Oliver L, Vallette FM, Pecqueur C, Jarry U, Scotet E. (2018) IL-21 Increases the Reactivity of Allogeneic Human Vγ9Vδ2 T Cells Against Primary Glioblastoma Tumors. J Immunother, 41 (5): 224-231. [PMID:29683891]

2. Lamprecht B, Kreher S, Anagnostopoulos I, Jöhrens K, Monteleone G, Jundt F, Stein H, Janz M, Dörken B, Mathas S. (2008) Aberrant expression of the Th2 cytokine IL-21 in Hodgkin lymphoma cells regulates STAT3 signaling and attracts Treg cells via regulation of MIP-3alpha. Blood, 112 (8): 3339-47. [PMID:18684866]

3. Lee JW, Yoo NJ, Soung YH, Kim HS, Park WS, Kim SY, Lee JH, Park JY, Cho YG, Kim CJ et al.. (2003) BRAF mutations in non-Hodgkin's lymphoma. Br J Cancer, 89 (10): 1958-60. [PMID:14612909]

4. Sethakorn N, Dulin NO. (2013) RGS expression in cancer: oncomining the cancer microarray data. J Recept Signal Transduct Res, 33 (3): 166-71. [PMID:23464602]